Brind.

Alvotech, a UK headquartered global pharmaceutical company, received European approval for its drug Mynzepli®.

1 report, 1 independent Updated Aug 21

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Alvotech Europe

Keep exploring

The entities involved

Alvotech
biotechnology company

Nothing else this week.
Europe
terrestrial continent located in north-western Eurasia
- The European Commission aims to strengthen homegrown AI capabilities while global advanced models face usage restrictions.Mon 17:49
- The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49

Coverage

Newest first; wire copies grouped

Aug 21GlobeNewswireAdvanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of variou